Entero Therapeutics

ENTO

Market cap $10.5M

BOCA RATON, FL / ACCESS Newswire / October 16, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("ENTO" or the "Company") a company pioneering innovation at the intersection of biotechnology and AI-driven energy infrastructure launches Grid AI Corp., to redefine how artificial intelligence infrastructure connects to the power grid. According to the company, the rise of artificial intelligence is driving the fastest infrastructure build-out in modern history and power is the new bottleneck.

BOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ: ENTO ) has reinvented itself in a way few public companies dare. By acquiring GRID AI , it has stepped directly into one of the most urgent races of the decade: making sure energy can keep pace with the accelerating appetite of artificial intelligence.

BOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ:ENTO ) didn't tiptoe into reinvention. It jumped.

U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.

Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions BOCA RATON, FL / ACCESS Newswire / October 1, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("ENTO" or the "Company") today announced it has acquired 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and device platform that enables utilities, retailers, and large power users to dynamically manage load and distributed energy resources ("DERs"). Over $50 million has been invested since 2019 to commercialize this revolutionary autonomous platform delivering Dynamic Load Shaping™ (DLS) and an Aggregation Management Platform (AMP) that orchestrate millions of behind-the-meter assets (including EV chargers, batteries, HVAC, water heaters and rooftop solar) using AI, machine learning and edge analytics to balance supply and demand in real time, creating a more reliable, resilient, and transactive grid.

Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions Boca Raton, Florida--(Newsfile Corp. - October 1, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("ENTO" or the "Company") today announced it has acquired 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and device platform that enables utilities, retailers, and large power users to dynamically manage load and distributed energy resources ("DERs"). Over $50 million has been invested since 2019 to commercialize this revolutionary autonomous platform delivering Dynamic Load Shaping™ (DLS) and an Aggregation Management Platform (AMP) that orchestrate millions of behind-the-meter assets (including EV chargers, batteries, HVAC, water heaters and rooftop solar) using AI, machine learning and edge analytics to balance supply and demand in real time, creating a more reliable, resilient, and transactive grid.

Boca Raton, Florida--(Newsfile Corp. - August 14, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that, it will effect a 1 for 3 reverse stock split of its common stock. The Company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on August 18, 2025.

Boca Raton, Florida--(Newsfile Corp. - August 11, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $3 million of pre-funded and common warrants. The entire transaction has been priced at the market under Nasdaq rules.

Calgary, Alberta--(Newsfile Corp. - June 13, 2025) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company") is pleased to announce that effective June 12, 2025, Eric Corbett has been appointed to the board of directors.

Boca Raton, Florida--(Newsfile Corp. - March 24, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the "Rescission Agreement") with 100% of the previous shareholders of ImmunogenX, LLC ("IMGX") in relation to the ImmunogenX Business Combination which was previously announced on December 18, 2023 and ultimately closed on March 14, 2024. The Rescission Agreement and its effects are subject to certain closing conditions, including Entero receiving shareholder approval which must occur on or before June 30, 2025.